Showing 2,541 - 2,560 results of 21,342 for search '(( significant clinical decrease ) OR ( significant decrease decrease ))', query time: 0.41s Refine Results
  1. 2541
  2. 2542
  3. 2543

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  4. 2544

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  5. 2545

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  6. 2546

    Baseline Characteristics of Study Participants. by Swati M. Surkar (8399427)

    Published 2025
    “…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”
  7. 2547

    Raw and processed data files. by Swati M. Surkar (8399427)

    Published 2025
    “…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”
  8. 2548
  9. 2549
  10. 2550
  11. 2551
  12. 2552
  13. 2553
  14. 2554
  15. 2555
  16. 2556
  17. 2557
  18. 2558
  19. 2559
  20. 2560